Skip to main content

Table 4 Univariate analyses of clinicopathological factors and molecular markers

From: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

   Number 3 yr DFS P 3 yr OS P
Tumor size < 5 cm
≥5 cm
121
30
78.6%
42.3%
0.038 92.1%
91.1%
0.952
Number of lymph nodes 4–9
≥10
79
72
89.8%
52.7%
< 0.001 100%
83.7%
0.001
Surgery MRM
BCS
120
31
70.0%
79.0%
0.808 90.9%
96.3%
0.953
Histology Ductal
Others
138
13
71.1%
76.9%
0.461 91.0%
100.0%
0.323
Histologic grade I, II
III
65
76
74.7%
69.5%
0.160 98.4%
84.3%
0.043
Endolymphatic tumor emboli absent
present
5
116
55.6%
71.7%
0.459 100%
91.6%
0.490
Close RM ≤2 mm
> 2 mm
5
146
70.8%
80.0%
0.590 91.5%
100%
0.475
ER (-)
(+)
68
83
64.9%
77.2%
0.013 83.4%
100%
0.006
PR (-)
(+)
92
59
68.3%
76.2%
0.136 87.1%
100%
0.121
p53 ≤25%
>25%
105
46
75.5%
62.1%
0.032 93.8%
87.8%
0.213
bcl-2 (-)
(+)
59
92
62.0%
77.6%
0.002 83.9%
97.4%
0.009
c-erbB2 (-) to (2+)
(3+)
121
30
74.3%
60.6%
0.112 96.3%
79.6%
0.050
Ki-67 < 5%
≥5%
94
56
85.6%
61.8%
0.146 91.0%
92.4%
0.631